Clinical trial
A Multicentre, Randomised, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of HSK7653 as Monotherapy in Chinese Patients With Type 2 Diabetes
NCT04556851 is registered in ClinicalTrials.gov with Sichuan Haisco Pharmaceutical Group Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicentre, Randomised, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of HSK7653 as Monotherapy in Chinese Patients With Type 2 Diabetes
- Lead sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 29, 2020
- Completion date
- August 8, 2022
- Enrollment
- 476 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.